The Cost Dynamics of Tuberculosis Comprehensive Programme: A Systematic Review
Main Article Content
Abstract
Tuberculosis (TB), as a significant global health challenge, remains leading the increasing burden of its disease. There is an essential requirement to understand and manage the costs of the TB treatment programme to ensure the sustainability of the TB control programme. The aims of this study are to synthesise existing literature on the economic implications of TB treatment programmes, focusing on the cost of the programme associated with drug-susceptible and drug-resistant TB. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and utilising the Population, Intervention, Comparison, Outcomes, and Study Design (PICOS) framework, studies published from 2013 to 2024 were systematically searched from PubMed, Scopus, and ScienceDirect. Only economic evaluations were included, resulting in 11 articles that provided diverse regional insights into TB costs. The review highlights the considerable financial burden of TB’s management, with diverse results from the literature. This study reveals that the combined strategy of the TB programme increases the cost-effectiveness at USD9,050.00 per disability-adjusted life year (DALY) and USD443.62 per TB case. The highest cost of the TB programme was reported for the passive case finding (PCF) at USD226.13 for adults. The funding gap was reported at USD301.62 million from 2018 to 2022. Effective TB management requires some comprehensive financial strategies to mitigate the economic burden that affects the direct and indirect national expenditure. Focusing on combining the strategies of passive and active case finding, increasing the treatment’s accessibility, and supporting the drug innovation are believed to be the strategies to enhance the achievement of the TB programme, as well as increasing the cost-effectiveness of its programme.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
World Health Organization (WHO). Global tuberculosis report 2023. Geneva: WHO; 2023.
U.S. Centers for Disease Control and Prevention (CDC). CDC fact sheet: The costly burden of drug-resistant TB disease in the U.S. [Internet]. Atlanta (GA): CDC; 2020 [Retrieved 2025 Oct 29]. Available at: https://stacks.cdc.gov/view/cdc/154504/cdc_154504_DS1.pdf
Carr W, Kurbatova E, Starks A, Goswami N, Allen L, Winston C. Interim guidance: 4-month rifapentine–moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(8):285–289.
Laurence YV, Griffiths UK, Vassall A. Costs to health services and the patient of treating tuberculosis: a systematic literature review. Pharmacoeconomics. 2015; 33(9):939–955. https://doi.org/10.1007/s40273-015-0279-6
Campbell JR, Nsengiyumva P, Chiang LY, Jamieson F, Khadawardi H, Mah HKH, et al. Costs of tuberculosis at 3 treatment centers, Canada, 2010–2016. Emerg Infect Dis. 2022; 28(9):1814–1823. https://doi.org/10.3201/eid2809.212024
Kohler S, Sitali N, Achar J, Paul N. Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan. ERJ Open Res. 2022; 8(1):00622-2021. https://doi.org/10.1183/23120541.00622-2021
Jo Y, Kagujje M, Johnson K, Dowdy D, Hangoma P, Chiliukutu L, et al. Costs and cost-effectiveness of a comprehensive tuberculosis case finding strategy in Zambia. PLoS One. 2021; 16(9):e0256531. https://doi.org/10.1371/journal.pone.0256531
Critical Appraisal Skills Programme (CASP). CASP checklist: for economic evaluations [Internet]. Oxford: CASP; 2024 [Retrieved 2024 Jun 6]. Available at: https://casp-uk.net/casp-tools-checklists/economic-evaluation-checklist/
Brough J, Martinez L, Hatherill M, Zar HJ, Lo NC, Andrews JR. Public health impact and cost-effectiveness of screening for active tuberculosis disease or infection among children in South Africa. Clin Infect Dis. 2023; 77(11):1544–1551. https://doi.org/10.1093/cid/ciad449
Gomez GB, Siapka M, Conradie F, Ndjeka N, Garfin AMC, Lomtadze N, et al. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines. BMJ Open. 2021; 11(12):e051521. https://doi.org/10.1136/bmjopen-2021-051521
Hussain H, Malik A, Ahmed J, Siddiqui S, Amanullah F, Creswell J, et al. Cost-effectiveness of household contact investigation for detection of tuberculosis in Pakistan. BMJ Open. 2021;11:e049658. https://doi.org/10.1136/bmjopen-2021-049658
Sekandi JN, Dobbin K, Oloya J, Okwera A, Whalen CC, Corso PS. Cost-effectiveness analysis of community active case finding and household contact investigation for tuberculosis case detection in urban Africa. PLoS ONE. 2015;10(2):e0117009. https://doi.org/10.1371/journal.pone.0117009
Chikovani I, Shengelia N, Marjanishvili N, Gabunia T, Khonelidze I, Cunnama L, et al. Cost of TB services in the public and private sectors in Georgia (No 2). Int J Tuberc Lung Dis. 2021;25(12):1019–1027. https://doi.org/10.5588/ijtld.21.0176
Jiang J, Lucas H, Long Q, Xin Y, Xiang L, Tang S. The effect of an innovative financing and payment model for tuberculosis patients on health service utilization in China: evidence from Hubei province of China. Int J Environ Res Public Health. 2019;16(14):2494. https://doi.org/10.3390/ijerph16142494
McAllister SM, Lestari BW, Sullivan T, Hadisoemarto PF, Afifah N, Apip RA, et al. Out-of-pocket costs for patients diagnosed with tuberculosis in different healthcare settings in Bandung, Indonesia. Am J Trop Med Hyg. 2020;103(3):1057–1064. https://doi.org/10.4269/ajtmh.19-0848
Hasan MZ, Ahmed S, Islam Z, Dorin F, Rabbani MG, Mehdi GG, et al. Costs of services and funding gap of the Bangladesh National Tuberculosis Control Programme 2016–2022: an ingredient based approach. PLoS ONE. 2023;18(6):e0286560. https://doi.org/10.1371/journal.pone.0286560
Menzies NA, Gomez GB, Bozzani F, Chatterjee S, Foster N, Baena IG, et al. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. Lancet Glob Health. 2016;4(11):e816–e826. https://doi.org/10.1016/S2214-109X(16)30265-0
Li R, Ruan Y, Sun Q, Wang X, Chen M, Zhang H, et al. Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrug-resistant tuberculosis in China: a before-and-after study. Lancet Glob Heal. 2015;3(4):e217–e228. https://doi.org/10.1016/S2214-109X(15)70021-5
Getahun B, Wubie M, Dejenu G, Manyazewal T. Tuberculosis care strategies and their economic consequences for patients: the missing link to end tuberculosis. Infect Dis Poverty. 2016;5(1):93. https://doi.org/10.1186/s40249-016-0187-9
World Health Organization. Financing for TB prevention, diagnostic and treatment services [Internet]. Geneva: World Health Organization; 2023 [Retrieved 2024 Nov 23]. Available at: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/financing-for-tb-prevention--diagnostic-and-treatment-services#:~:text=The total reported gap in,amounted to US$ 1.6 billion.&text=In 2022%2C 62 low- and,na
Sejie GA, Mahomed OH. Mapping the effectiveness of the community tuberculosis care programs: a systematic review. Syst Rev. 2023;12(1):135. https://doi.org/10.1186/s13643-023-02296-0
Siregar FA, Makmur T. The role of socio-cultural and environmental risk factors on the incidence of tuberculosis infection. Proceeding 4th Int Conf Public Health. 2018;4(2):11–17. https://doi.org/10.17501/24246735.2018.4202
Muttamba W, Kirenga B, Ssengooba W, Sekibira R, Katamba A, Joloba ML. Prevalence of tuberculosis risk factors among bacteriologically negative and bacteriologically confirmed tuberculosis patients from five regional referral hospitals in Uganda. Am J Trop Med Hyg. 2019;100(2):386–391. https://doi.org/10.4269/ajtmh.18-0281
Nurjannah A, Rahmalia FY, Paramesti HR, Laily LA, Pradani FKPH, Nisa AA, et al. Determinan sosial tuberculosis di Indonesia. J Penelit dan Pengemb Kesehat Masy Indones. 2022;3(1):65–76.
Khariyani AM, Kismiantini K, Setiawan EP. Analisis faktor-faktor yang memengaruhi jumlah penderita tuberkulosis menggunakan geographically weighted regression di Provinsi Jawa Timur. Pros Semin Nas Mat Stat dan Apl. 2022;2:16–26.
Kang Y, Jo E-J, Eom JS, Kim M-H, Lee K, Kim KU, et al. Treatment outcomes of patients with multidrug-resistant tuberculosis: comparison of pre- and post-public–private mix periods. Tuberc Respir Dis. 2021;84(1):74–83. https://doi.org/10.4046/trd.2020.0093
Jayasooriya S, Dimambro-Denson F, Beecroft C, Balen J, Awokola B, Mitchell C, et al. Patients with presumed tuberculosis in sub-Saharan Africa that are not diagnosed with tuberculosis: a systematic review and meta-analysis. Thorax. 2023;78(1):50–60. https://doi.org/10.1136/thoraxjnl-2021-217663
Vishwakarma D, Ravi RP. Prevalence and determinants of depression among patients with tuberculosis in Municipal Corporation of Sagar District in the State of Madhya Pradesh, India. Indian J Public Health Res Dev. 2020;11(5):84–92. https://doi.org/10.37506/ijphrd.v11i5.9295
Sutriyawan A, Akbar H. Factors related to the incidence of tuberculosis in Garuda Health Center Bandung, West Java Province, Indonesia. Int J Contemp Pathol. 2022;8(1):22–29. https://doi.org/10.37506/ijcpath.v8i1.17844
Das NP, Panda A. Clinical epidemiology of multidrug resistant tuberculosis in a nodal drug resistant-TB centre in Southern Odisha: a cross-sectional study. Natl J Lab Med. 2022;11(2):BO01–BO04. https://doi.org/10.7860/NJLM/2022/53247.2591
Moyo N, Tay EL, Trauer JM, Burke L, Jackson J, Commons RJ, et al. Tuberculosis notifications in regional Victoria, Australia: implications for public health care in a low incidence setting. PLoS ONE. 2023;18(3):e0282884. https://doi.org/10.1371/journal.pone.0282884
Wingfield T, Tovar MA, Huff D, Boccia D, Montoya R, Ramos E, et al. A randomized controlled study of socioeconomic support to enhance tuberculosis prevention and treatment, Peru. Bull World Health Organ. 2017;95(4):270–280. https://doi.org/10.2471/BLT.16.170167
Saunders MJ, Tovar MA, Collier D, Baldwin MR, Montoya R, Valencia T, et al. Active and passive case-finding in tuberculosis-affected households in Peru: a 10-year prospective cohort study. Lancet Infect Dis. 2019;19(5):519–528. https://doi.org/10.1016/S1473-3099(18)30753-9
Kamenye E, Iipinge S, Van Dyk A. Implementation and evaluation of communication guidelines for the nurses caring for patients diagnosed with tuberculosis. Int J Health. 2017;5(2):126–128. https://doi.org/10.14419/ijh.v5i2.8286
WHO. Global Tuberculosis Report 2022. TB prevention [Internet]. Geneva: WHO; 2023 [Retrieved 2023 Sep 29]. Available at: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022/tb-prevention#:~:text=4.-,TB prevention,are discussed in Section 6.3
Datiko DG, Jerene D, Suarez P. Stigma matters in ending tuberculosis: nationwide survey of stigma in Ethiopia. BMC Public Health. 2020;20(1):190. https://doi.org/10.1186/s12889-019-7915-6
European Centre for Disease Prevention and Control (ECDC). Examples of interventions to manage tuberculosis in vulnerable groups [Internet]. Solna (Sweden): ECDC; 2016 [Retrieved 2019 Jun 16]. Available at: https://www.ecdc.europa.eu/en/tuberculosis/prevention-and-control/examples-interventions
André E, Rusumba O, Evans CA, Ngongo P, Sanduku P, Elvis MM, et al. Patient-led active tuberculosis case-finding in the Democratic Republic of the Congo. Bull World Health Organ. 2018;96(8):522–530. https://doi.org/10.2471/BLT.17.203968
US Preventive Services Task Force. Screening for latent tuberculosis infection in adults: US Preventive Services Task Force recommendation statement. JAMA. 2023;329(17):1487–1494. https://doi.org/10.1001/jama.2023.4899
Ekundayo EO, Onuka O, Mustapha, G, Geoffrey MW. Active case finding of pulmonary tuberculosis among prison inmates in Aba Federal Prison, Abia State, Nigeria. Adv Infect Dis. 2015;5(1):57–62. https://doi.org/10.4236/aid.2015.51006
Brooks MB, Pingali V, Nicholson T, Keshavjee S. Cost of inaction: a framework to estimate the economic cost of missing a patient with tuberculosis in the Indian context. BMJ Open. 2023;13: e070717. https://doi.org/10.1136/bmjopen-2022-070717
van den Hof S, Collins D, Hafidz F, Beyene D, Tursynbayeva A, Tiemersma E. The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan. BMC Infect Dis. 2016;16(1):470. https://doi.org/10.1186/s12879-016-1802-x
Bao L, Razbek J, Zhang Y, Xu W, Mao H, Cao M, et al. Cost-effectiveness analysis of tuberculosis detection strategy based on close contact cohort. Preprint, Research Square. 2022. https://doi.org/10.21203/rs.3.rs-1804810/v1
Loureiro RB, Maciel ELN, Caetano R, Peres RL, Fregona G, Golub JE, et al. Cost-effectiveness of QuantiFERON-TB Gold In-Tube versus tuberculin skin test for diagnosis and treatment of latent tuberculosis infection in primary health care workers in Brazil. PLoS ONE. 2019;14(11):e0225197. https://doi.org/10.1371/journal.pone.0225197
Marx FM, Cohen T, Menzies NA, Salomon JA, Theron G, Yaesoubi R. Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis. Lancet Glob Health. 2020;8(9):e1223–e1233. https://doi.org/10.1016/S2214-109X(20)30227-8
d’Elbée M, Harker M, Mafirakureva N, Nanfuka M, Nguyet MHTN, Taguebue J-V, et al. Cost-effectiveness and budget impact of decentralising childhood tuberculosis diagnosis: a mathematical modelling study in six high tuberculosis incidence countries. eClinicalMedicine. 2024;70:102528. https://doi.org/10.1101/2023.09.26.23295962
Thompson RR, Nalugwa T, Oyuku D, Tucker A, Nantale M, Nakaweesa A, et al. Multicomponent strategy with decentralised molecular testing for tuberculosis in Uganda: a cost and cost-effectiveness analysis. Lancet Glob Health. 2023;11(2):e278–e286. https://doi.org/10.1016/S2214-109X(22)00509-5
Denysiuk R, Silva CJ, Torres DFM. Multiobjective approach to optimal control for a tuberculosis model. Optim Methods Softw. 2015;30(5):893–910. https://doi.org/10.1080/10556788.2014.994704
de Mello‐Sampayo F. Patients’ out-of-pocket expenses analysis of presurgical teledermatology. Cost Eff Resour Alloc. 2019;17(1):18. https://doi.org/10.1186/s12962-019-0186-3
McIntosh AI, Jenkins HE, White LF, Barnard M, Thomson DR, Dolby T, et al. Using routinely collected laboratory data to identify high rifampicin-resistant tuberculosis burden communities in the Western Cape Province, South Africa: a retrospective spatiotemporal analysis. PLoS Med. 2018;15(8):e1002638. https://doi.org/10.1371/journal.pmed.1002638